| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
384,739 |
327,225 |
$60.25M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
389,956 |
326,934 |
$6.30M |
| 00003 |
Internal/system code - not a standard HCPCS code |
11,170 |
9,287 |
$2.46M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
41,040 |
38,789 |
$1.31M |
| 59425 |
|
12,486 |
7,105 |
$1.08M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
12,316 |
12,223 |
$652K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
7,942 |
7,762 |
$447K |
| 98941 |
Chiropractic manipulative treatment; spinal, 3-4 regions |
17,021 |
11,815 |
$406K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
32,127 |
30,129 |
$389K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
5,470 |
5,367 |
$387K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
7,077 |
6,922 |
$365K |
| 99215 |
Prolong outpt/office vis |
3,295 |
2,778 |
$271K |
| 90791 |
Psychiatric diagnostic evaluation |
3,917 |
3,585 |
$266K |
| 92551 |
|
20,707 |
20,238 |
$260K |
| 90837 |
Psychotherapy, 53 minutes with patient |
4,051 |
3,366 |
$249K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
7,778 |
7,702 |
$230K |
| 90834 |
Psychotherapy, 45 minutes with patient |
6,868 |
5,391 |
$230K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
2,090 |
2,083 |
$195K |
| 98940 |
|
9,076 |
7,032 |
$158K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,347 |
1,307 |
$152K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
3,751 |
3,728 |
$142K |
| 90686 |
|
8,874 |
8,795 |
$135K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,611 |
2,581 |
$133K |
| 99243 |
|
1,504 |
1,442 |
$128K |
| 0002A |
|
2,974 |
1,712 |
$115K |
| 0001A |
|
2,934 |
1,697 |
$102K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
4,568 |
4,548 |
$96K |
| 90715 |
|
4,268 |
4,230 |
$96K |
| 90651 |
|
3,703 |
3,650 |
$89K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
1,480 |
1,479 |
$89K |
| 90832 |
Psychotherapy, 30 minutes with patient |
3,007 |
2,415 |
$85K |
| 90670 |
|
3,949 |
3,886 |
$76K |
| 99173 |
|
20,936 |
20,470 |
$76K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
13,080 |
6,553 |
$68K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
7,331 |
7,308 |
$55K |
| 90648 |
|
3,621 |
3,573 |
$53K |
| 0003A |
|
1,234 |
752 |
$49K |
| 90633 |
|
2,997 |
2,935 |
$49K |
| 90734 |
|
2,587 |
2,539 |
$46K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
9,098 |
8,868 |
$45K |
| 59430 |
|
499 |
426 |
$43K |
| 90620 |
|
1,383 |
1,372 |
$43K |
| 81003 |
|
32,805 |
31,458 |
$39K |
| 90723 |
|
2,737 |
2,710 |
$39K |
| 90716 |
|
1,373 |
1,346 |
$37K |
| 85018 |
|
27,657 |
26,928 |
$36K |
| 90682 |
|
1,253 |
1,252 |
$35K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
807 |
797 |
$35K |
| J3490 |
Unclassified drugs |
503 |
497 |
$35K |
| 0072A |
|
838 |
452 |
$35K |
| 0071A |
|
816 |
431 |
$33K |
| 97814 |
|
3,059 |
1,953 |
$31K |
| 90750 |
|
169 |
169 |
$27K |
| 90710 |
|
1,511 |
1,490 |
$27K |
| 90707 |
|
1,081 |
1,060 |
$25K |
| 90696 |
|
1,380 |
1,358 |
$24K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
7,459 |
7,398 |
$23K |
| 92250 |
|
2,469 |
2,467 |
$22K |
| 97813 |
|
3,001 |
2,054 |
$21K |
| 90680 |
|
1,466 |
1,457 |
$19K |
| G9920 |
Screening performed and negative |
947 |
947 |
$19K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,209 |
4,027 |
$16K |
| 90700 |
|
866 |
849 |
$16K |
| 81025 |
|
6,638 |
6,401 |
$14K |
| 93000 |
|
524 |
522 |
$14K |
| 92083 |
|
1,306 |
1,304 |
$13K |
| 90677 |
|
332 |
332 |
$12K |
| 99383 |
|
129 |
127 |
$12K |
| 81002 |
|
14,837 |
8,364 |
$11K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
75 |
75 |
$11K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,912 |
1,798 |
$8K |
| 99381 |
|
157 |
155 |
$8K |
| 92133 |
|
570 |
569 |
$8K |
| 0031A |
|
227 |
138 |
$7K |
| 90656 |
|
648 |
647 |
$7K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
188 |
179 |
$7K |
| 90619 |
|
472 |
471 |
$5K |
| 90647 |
|
452 |
451 |
$5K |
| 92015 |
Determination of refractive state |
10,798 |
10,794 |
$5K |
| 0013A |
|
114 |
65 |
$5K |
| 0053A |
|
70 |
70 |
$4K |
| 0124A |
|
87 |
87 |
$4K |
| 90671 |
|
244 |
243 |
$3K |
| 99384 |
|
24 |
24 |
$2K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
252 |
246 |
$2K |
| 90673 |
|
75 |
75 |
$2K |
| 0052A |
|
34 |
34 |
$2K |
| 90732 |
|
24 |
24 |
$2K |
| 99242 |
|
22 |
22 |
$2K |
| 92134 |
|
617 |
615 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
55 |
48 |
$2K |
| G8431 |
Screening for depression is documented as being positive and a follow-up plan is documented |
194 |
194 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
142 |
140 |
$1K |
| 87807 |
|
306 |
303 |
$1K |
| Q3014 |
Telehealth originating site facility fee |
41 |
41 |
$1K |
| 92002 |
|
16 |
16 |
$1K |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
149 |
149 |
$1K |
| 92557 |
|
12 |
12 |
$1K |
| 92567 |
|
25 |
25 |
$1K |
| 86580 |
|
322 |
310 |
$1K |
| 90681 |
|
63 |
63 |
$1K |
| 82962 |
|
544 |
515 |
$926.21 |
| 0054A |
|
14 |
14 |
$871.00 |
| 90672 |
|
56 |
54 |
$792.00 |
| 90662 |
|
64 |
64 |
$585.00 |
| 97810 |
|
55 |
43 |
$561.54 |
| 69210 |
|
19 |
14 |
$530.00 |
| 76514 |
|
73 |
73 |
$492.68 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
65 |
64 |
$488.97 |
| 0121A |
|
13 |
13 |
$469.00 |
| 91320 |
|
35 |
35 |
$393.30 |
| 97811 |
|
30 |
16 |
$355.27 |
| 83655 |
|
21 |
21 |
$223.23 |
| 99188 |
|
185 |
185 |
$148.00 |
| G0511 |
Rural health clinic or federally qualified health center (rhc or fqhc) only, general care management, 20 minutes or more of clinical staff time for chronic care management services or behavioral health integration services directed by an rhc or fqhc practitioner (physician, np, pa, or cnm), per calendar month |
1,261 |
1,259 |
$144.00 |
| 92020 |
|
15 |
15 |
$134.01 |
| 90480 |
|
12 |
12 |
$120.00 |
| T1014 |
Telehealth transmission, per minute, professional services bill separately |
41 |
41 |
$38.52 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
341 |
331 |
$17.68 |
| G2025 |
Payment for a telehealth distant site service furnished by a rural health clinic (rhc) or federally qualified health center (fqhc) only |
94 |
82 |
$4.30 |
| 3075F |
|
4,475 |
4,322 |
$0.00 |
| Z1032 |
|
346 |
343 |
$0.00 |
| Z1034 |
|
12,224 |
7,122 |
$0.00 |
| 3079F |
|
9,112 |
8,578 |
$0.00 |
| 3074F |
|
23,164 |
21,308 |
$0.00 |
| 3044F |
|
655 |
621 |
$0.00 |
| 3008F |
|
18,188 |
16,927 |
$0.00 |
| 2001F |
|
18,193 |
16,932 |
$0.00 |
| 3080F |
|
2,309 |
2,200 |
$0.00 |
| 1036F |
|
20,008 |
16,554 |
$0.00 |
| G0008 |
Administration of influenza virus vaccine |
220 |
220 |
$0.00 |
| Z1038 |
|
81 |
66 |
$0.00 |
| 3052F |
|
172 |
161 |
$0.00 |
| 3048F |
|
92 |
91 |
$0.00 |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
42 |
40 |
$0.00 |
| S0257 |
Counseling and discussion regarding advance directives or end of life care planning and decisions, with patient and/or surrogate (list separately in addition to code for appropriate evaluation and management service) |
45 |
43 |
$0.00 |
| 0011A |
|
25 |
25 |
$0.00 |
| 3077F |
|
5,140 |
4,793 |
$0.00 |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
455 |
450 |
$0.00 |
| 3051F |
|
218 |
206 |
$0.00 |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
500 |
499 |
$0.00 |
| 3078F |
|
21,711 |
20,048 |
$0.00 |
| 3046F |
|
479 |
429 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
121 |
118 |
$0.00 |
| 90461 |
|
14 |
14 |
$0.00 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
14 |
14 |
$0.00 |